Shi, Yuankai
Chinese Academy of Medical Sciences & Peking Union Medical College · Cancer Hospital of Chinese Academy of Medical Sciences
2 papers on CoChatORCID 0000-0002-8685-6744
Most cited papers
- Verified
Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial
Shi, Y., Fang, J., Xing, L., Yao, Y., Zhang, J., Liu, L., Wang, Y., Hu, C., Xiong, J., Liu, Z., et al. (2025) · Nature Medicine
Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling
Cited by 42
- Verified
Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation from a phase I/IIa study
Shi, Y., Zhou, J., Zhao, Y., Zhu, B., Zhang, L., Li, X., Fang, J., Shi, J., Zhuang, Z., Yang, S., et al. (2023) · BMC Medicine
Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment
Cited by 13
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free